Dr. Densmore is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1215 Lee St
Charlottesville, VA 22908Phone+1 434-924-9333Fax+1 434-244-7526
Education & Training
- University of Virginia Medical CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
- University of Virginia Medical CenterResidency, Internal Medicine, 1995 - 1998
- University of Virginia School of MedicineClass of 1995
Certifications & Licensure
- VA State Medical License 1997 - 2026
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2012
Clinical Trials
- Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2008 Feb 29
- Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2008 Jul 01
Publications & Presentations
PubMed
- 272 citationsRituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymphocytic LeukemiaAdam D. Kennedy, Paul V. Beum, Michael D. Solga, David J. DiLillo, Margaret A. Lindorfer
Journal of Immunology. 2004-03-01 - 118 citationsThrice-Weekly Low-Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in Chronic Lymphocytic LeukemiaMichael E. Williams, John J. Densmore, Andrew W. Pawluczkowycz, Paul V. Beum, Adam D. Kennedy
Journal of Immunology. 2006-11-15 - 96 citationsPerifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I...Paul G. Richardson, Jeff Wolf, Andrzej Jakubowiak, Jeff Zonder, Sagar Lonial
Journal of Clinical Oncology. 2011-11-10
Press Mentions
- A Dose of InspirationMay 31st, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: